Literature DB >> 33193852

Expression of TRPC1 and SBEM protein in breast cancer tissue and its relationship with clinicopathological features and prognosis of patients.

Yongqing Zhang1, Xiaoqin Lun1, Weiling Guo1.   

Abstract

This study investigated the relationship of the expression of transient receptor potential channel 1 (TRPC1), small breast epithelial mucin (SBEM) in breast cancer tissues with clinical pathological features and prognosis of patients. Altogether 50 patients with breast cancer who were treated in Weifang People's hospital from April 2017 to November 2018 were selected, and the mRNA and protein differences of TRPC1 and SBEM in breast cancer patients and normal breast cancer tissues were detected by qRT-PCR and Western blot. Spearman test was used for correlation analysis. Logistic univariate and multivariate analysis were performed on the risk factors related to breast cancer metastasis in breast cancer patients. The expression of TRPC1 and SBEM in breast cancer tissues was significantly higher than that in normal breast tissues (P<0.001). The mRNA expression of TRPC1, SBEM and protein was not related to age, tumor size and tissue grade of breast cancer patients, but related to TNM stage, clinical stage and lymph node metastasis (P<0.001). The relative expression of TRPC1 was positively correlated with clinical stage of breast cancer (r=0.992, P<0.001). The relative expression of SBEM was positively correlated with the clinical stage of breast cancer (r=0.853, P<0.001). The relative expression of TRPC1 was positively correlated with TNM staging of breast cancer (r=0.860, P<0.001). The relative expression of SBEM was positively correlated with TNM staging of breast cancer (r=0.880, P<0.001). Multivariate conditional Logistic regression analysis showed that TNM staging, TRPC1, SBEM were independent risk factors for malignant breast cancer metastasis. On the contrary, expression of TRPC1 and SBEM in breast cancer tissues was up-regulated. TRPC1 and SBEM may be involved in the process of breast cancer occurrence, development and metastasis, and can be used as potential tissue biomarkers in diagnosis of breast cancer metastasis and disease assessment.
Copyright © 2020, Spandidos Publications.

Entities:  

Keywords:  SBEM; TRPC1; biomarkers; breast cancer; clinicopathological features; prognosis

Year:  2020        PMID: 33193852      PMCID: PMC7656111          DOI: 10.3892/ol.2020.12255

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  24 in total

1.  Triple-negative breast cancer cell line sensitivity to englerin A identifies a new, targetable subtype.

Authors:  Corena V Grant; Chase M Carver; Shayne D Hastings; Karthik Ramachandran; Madesh Muniswamy; April L Risinger; John A Beutler; Susan L Mooberry
Journal:  Breast Cancer Res Treat       Date:  2019-06-22       Impact factor: 4.872

2.  Recommendations of the Brazilian Society of Endocrinology and Metabology (SBEM) for the diagnosis and treatment of hypovitaminosis D.

Authors:  Sergio Setsuo Maeda; Victoria Z C Borba; Marília Brasilio Rodrigues Camargo; Dalisbor Marcelo Weber Silva; João Lindolfo Cunha Borges; Francisco Bandeira; Marise Lazaretti-Castro
Journal:  Arq Bras Endocrinol Metabol       Date:  2014-07

3.  Journey to the centre of the cell: Virtual reality immersion into scientific data.

Authors:  Angus P R Johnston; James Rae; Nicholas Ariotti; Benjamin Bailey; Andrew Lilja; Robyn Webb; Charles Ferguson; Sheryl Maher; Thomas P Davis; Richard I Webb; John McGhee; Robert G Parton
Journal:  Traffic       Date:  2017-11-21       Impact factor: 6.215

Review 4.  Immunotherapy and targeted therapy combinations in metastatic breast cancer.

Authors:  Francisco J Esteva; Vanessa M Hubbard-Lucey; Jun Tang; Lajos Pusztai
Journal:  Lancet Oncol       Date:  2019-03       Impact factor: 41.316

5.  An automated epifluorescence microscopy imaging assay for the identification of phospho-AKT level modulators in breast cancer cells.

Authors:  Elke Kaemmerer; Dane Turner; Amelia A Peters; Sarah J Roberts-Thomson; Gregory R Monteith
Journal:  J Pharmacol Toxicol Methods       Date:  2018-02-10       Impact factor: 1.950

Review 6.  Microcalcifications in breast cancer: From pathophysiology to diagnosis and prognosis.

Authors:  S O'Grady; M P Morgan
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2018-04-21       Impact factor: 10.680

7.  Blocking CXCR4 alleviates desmoplasia, increases T-lymphocyte infiltration, and improves immunotherapy in metastatic breast cancer.

Authors:  Ivy X Chen; Vikash P Chauhan; Jessica Posada; Mei R Ng; Michelle W Wu; Pichet Adstamongkonkul; Peigen Huang; Neal Lindeman; Robert Langer; Rakesh K Jain
Journal:  Proc Natl Acad Sci U S A       Date:  2019-01-30       Impact factor: 11.205

8.  MALAT1 long non-coding RNA and breast cancer.

Authors:  Gayatri Arun; David L Spector
Journal:  RNA Biol       Date:  2019-03-22       Impact factor: 4.766

9.  Targeting promiscuous heterodimerization overcomes innate resistance to ERBB2 dimerization inhibitors in breast cancer.

Authors:  Sean P Kennedy; Jeremy Z R Han; Neil Portman; Max Nobis; Jordan F Hastings; Kendelle J Murphy; Sharissa L Latham; Antonia L Cadell; Dushan Miladinovic; Gabriella R Marriott; Yolande E I O'Donnell; Robert F Shearer; James T Williams; Amaya Garcia Munoz; Thomas R Cox; D Neil Watkins; Darren N Saunders; Paul Timpson; Elgene Lim; Walter Kolch; David R Croucher
Journal:  Breast Cancer Res       Date:  2019-03-21       Impact factor: 6.466

10.  Differential expression of store-operated calcium- and proliferation-related genes in hepatocellular carcinoma cells following TRPC1 ion channel silencing.

Authors:  Cigdem Selli; Dominic A Pearce; Andrew H Sims; Metiner Tosun
Journal:  Mol Cell Biochem       Date:  2016-07-22       Impact factor: 3.396

View more
  6 in total

1.  Modulated TRPC1 Expression Predicts Sensitivity of Breast Cancer to Doxorubicin and Magnetic Field Therapy: Segue Towards a Precision Medicine Approach.

Authors:  Yee Kit Tai; Karen Ka Wing Chan; Charlene Hui Hua Fong; Sharanya Ramanan; Jasmine Lye Yee Yap; Jocelyn Naixin Yin; Yun Sheng Yip; Wei Ren Tan; Angele Pei Fern Koh; Nguan Soon Tan; Ching Wan Chan; Ruby Yun Ju Huang; Jing Ze Li; Jürg Fröhlich; Alfredo Franco-Obregón
Journal:  Front Oncol       Date:  2022-01-24       Impact factor: 5.738

2.  Transient Receptor Potential Channel 1 Potentially Serves as a Biomarker Indicating T/TNM Stages and Predicting Long-Term Prognosis in Patients With Renal Cell Carcinoma.

Authors:  Liang Chen; Guang Shan; Minghuan Ge; Huijun Qian; Yue Xia
Journal:  Front Surg       Date:  2022-04-25

3.  The TRPC1 Channel Forms a PI3K/CaM Complex and Regulates Pancreatic Ductal Adenocarcinoma Cell Proliferation in a Ca2+-Independent Manner.

Authors:  Julie Schnipper; Sana Kouba; Frédéric Hague; Alban Girault; Pierre Rybarczyk; Marie-Sophie Telliez; Stéphanie Guénin; Riad Tebbakha; Henri Sevestre; Ahmed Ahidouch; Stine Falsig Pedersen; Halima Ouadid-Ahidouch
Journal:  Int J Mol Sci       Date:  2022-07-18       Impact factor: 6.208

4.  Aberrant TRPC1 expression reflects stromal cervical invasion, lymphovascular invasion, elevated FIGO stage, and poor survival in resectable endometrial carcinoma patients.

Authors:  Yi Wang; Chun Zhang
Journal:  J Clin Lab Anal       Date:  2022-06-26       Impact factor: 3.124

5.  TRPs in Ovarian Serous Cystadenocarcinoma: The Expression Patterns, Prognostic Roles, and Potential Therapeutic Targets.

Authors:  Cheng Zhang; Cong Xu; Chuanshun Ma; Qinghua Zhang; Siyuan Bu; Dao-Lai Zhang; Liting Yu; Hongmei Wang
Journal:  Front Mol Biosci       Date:  2022-06-24

6.  Dysregulated transient receptor potential channel 1 expression and its correlation with clinical features and survival profile in surgical non-small-cell lung cancer patients.

Authors:  Changjiang Ke; Shenghua Long
Journal:  J Clin Lab Anal       Date:  2022-02-02       Impact factor: 2.352

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.